Brief: CymaBay Submits New Drug Application To FDA For Seladelpar For The Treatment Of Primary Biliary Cholangitis
15/12/2023 13:08
Dec 15 (Reuters) - Cymabay Therapeutics Inc CBAY.O :
* CYMABAY SUBMITS NEW DRUG APPLICATION TO FDA FOR SELADELPAR
FOR
THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
* CYMABAY THERAPEUTICS INC - NDA IS SUPPORTED BY DATA
EVALUATING
SELADELPAR EFFICACY AND SAFETY IN OVER 500 PATIENTS
* CYMABAY THERAPEUTICS INC - INTENDS TO FILE MARKETING
AUTHORIZATION APPLICATIONS TO EMA AND U.K. MHRA IN FIRST HALF OF
2024
Source text for Eikon: ID:nPnc01jDFa
Further company coverage: CBAY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CymaBay Therapeutics
See all newsBrief: CymaBay Says EMA Accepted For Review The Marketing Authorization Application For Seladelpar
U.S. RESEARCH ROUNDUP-Bruker Corp, Cymabay Therapeutics, SSR Mining
U.S. RESEARCH ROUNDUP-An2 Therapeutics, Par Technology, Trimble
U.S. STOCKS ON THE MOVE-Perpetua Resources, Nvidia, SiriusXM
U.S. STOCKS ON THE MOVE-Lowe's, Bit Digital Snap